These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 25239825)

  • 1. C-peptide replacement therapy as an emerging strategy for preventing diabetic vasculopathy.
    Bhatt MP; Lim YC; Ha KS
    Cardiovasc Res; 2014 Nov; 104(2):234-44. PubMed ID: 25239825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
    Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
    Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can C-peptide mediated anti-inflammatory effects retard the development of microvascular complications of type 1 diabetes?
    Luppi P; Kallas Å; Wahren J
    Diabetes Metab Res Rev; 2013 Jul; 29(5):357-62. PubMed ID: 23463541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple Cell Signalling Pathways of Human Proinsulin C-Peptide in Vasculopathy Protection.
    Souto SB; Campos JR; Fangueiro JF; Silva AM; Cicero N; Lucarini M; Durazzo A; Santini A; Souto EB
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G
    J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-peptide and chronic complications in patients with type-2 diabetes and the metabolic syndrome.
    Mavrakanas T; Frachebois C; Soualah A; Aloui F; Julier I; Bastide D
    Presse Med; 2009 Oct; 38(10):1399-403. PubMed ID: 19419831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway.
    Litwinoff E; Hurtado Del Pozo C; Ramasamy R; Schmidt AM
    Clin Pharmacol Ther; 2015 Aug; 98(2):135-44. PubMed ID: 25974754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of VEGF-mediated microvascular permeability by C-peptide in diabetic mice.
    Lim YC; Bhatt MP; Kwon MH; Park D; Lee S; Choe J; Hwang J; Kim YM; Ha KS
    Cardiovasc Res; 2014 Jan; 101(1):155-64. PubMed ID: 24142430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of blood glucose concentrations on the development of chronic complications of diabetes mellitus.
    Swidan SZ; Montgomery PA
    Pharmacotherapy; 1998; 18(5):961-72. PubMed ID: 9758308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micro- and macrovascular outcomes in Type 2 diabetic patients treated with insulin glulisine or human regular insulin: a retrospective database analysis.
    Kress S; Kostev K; Dippel FW; Giani G; Rathmann W
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):821-9. PubMed ID: 22578200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Von Willebrand factor in diabetic angiopathy.
    Kessler L; Wiesel ML; Attali P; Mossard JM; Cazenave JP; Pinget M
    Diabetes Metab; 1998 Sep; 24(4):327-36. PubMed ID: 9805643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies.
    Fitchett D
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S176-82. PubMed ID: 26654861
    [No Abstract]   [Full Text] [Related]  

  • 13. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
    Bajaj M; Jialal I
    Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
    [No Abstract]   [Full Text] [Related]  

  • 14. [Risks and side effects of intensified insulin therapy].
    Honegger R; Spinas GA
    Wien Med Wochenschr; 1997; 147(9):226-30. PubMed ID: 9281237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symposium on treatment of diabetic complications. 5. Strict glycemic control and diabetic microvascular complications.
    Shichiri M
    Intern Med; 1997 Feb; 36(2):144-7. PubMed ID: 9099605
    [No Abstract]   [Full Text] [Related]  

  • 16. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
    Savage S; Estacio RO; Jeffers B; Schrier RW
    Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of oral hypoglycemic agents in therapy and prevention of macrovascular complications.
    Krall LP
    Horm Metab Res Suppl; 1985; 15():98-101. PubMed ID: 3908284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 2 diabetes mellitus: prevention of macrovascular complications.
    Meeuwisse-Pasterkamp SH; van der Klauw MM; Wolffenbuttel BH
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):323-41. PubMed ID: 18327994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arterial stiffness in diabetes mellitus.
    Prenner SB; Chirinos JA
    Atherosclerosis; 2015 Feb; 238(2):370-9. PubMed ID: 25558032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Blood pressure control in patients with diabetes mellitus. Focus on postprandial blood glucose values and cardiovascular risk].
    MMW Fortschr Med; 2012 Feb; 154(3):82-3. PubMed ID: 22458177
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.